Hyperthermia Treatment in Conjunction With Mitomycin C Versus Bacillus Calmette-Guérin Immunotherapy (BCG) for Superficial Bladder Cancer

Exclusion Criteria

• •Bladder tumors other than TCC
• •Coexistence of another primary malignant tumor other than BCC of the skin
• •TCC of the bladder involving the urethra or upper urinary tract
• •Previous history of TCC stage T2 or higher
• •Clinical presence or previous history of regional spreading or distant metastases
• •Intravesical MMC treatments during the last 12 months
• •Previous intravesical BCG therapy (Any intravesical BCG therapy in the last 24 months, or More than 6 BCG intravesical instillations in the last 48 months.
• •Previous pelvic radiotherapy or systemic chemotherapy
• •Partial cystectomy
• •Diverticle of bladder larger than 1cm in diameter
• •Residual urine \> 100cc measured by uroflowmetry
• •Bladder volume \< 150cc measured by ultrasound
• •Urinary incontinence (more than one wet pad a day)
• •Urethral stricture impeding 20F catheterization
• •Urethral bleeding or persistent hematuria
• •Active intractable or uncontrollable UTI
• •Active tuberculosis or BCG infection
• •Patients who experienced BCG life threatening sepsis
• •Known allergy to MMC or BCG
• •Known impaired immune response, positive HIV serology, patients receiving systemic steroids or immunosuppressive therapy
• •Hematological disorders; leukocytes \< 3500, platelets \< 100,000
• •Kidney or liver function disorders (more than 1.5 times upper normal limit)
• •Pregnant or lactating women
• •Patients who cannot be followed up properly or are unable to collaborate